Recent innovations in DNA-modifying will revolutionize the treatment of many diseases and prompt crucial discussions.

In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...

Gene editing techniques may eventually allow trisomy to be treated at the cellular level, according to an in vitro ...

The Recombinant DNA Technology Market size is expected to be worth around USD 1288.5 Bn by 2032 from USD 786.7 Bn in 2023, growing at a CAGR of 5.8% As scientific and technological advancements ...

The global Gene Editing Market was valued at $5.1 billion in 2022 and is projected to reach $16.2 billion by 2030, growing at ...

Gene editing techniques may eventually allow trisomy to be treated at the cellular level, according to an in vitro ...

Mammoth Biosciences researchers have developed NanoCas, an ultracompact CRISPR nuclease, demonstrating its ability to perform ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Due to proteostasis stress induced by aging or disease, misfolded proteins can form toxic intermediate species of aggregates and eventually mature into less toxic inclusion bodies (IBs). Here, using a ...